CSL Ltd announced its half year
results to December, with net profit
after tax up 3% on the year before
period to US$646m.
This was on revenue of US$2.69b ,
up 5% on the previous period.
Its immunoglobulin product sales
grew 7% to US$1.09b in a global
market which remained “robust”,
the company said.
CSL ceo Paul Perreault said a new
drug the company was developing
to stop recurring heart attacks had
the potential to “transform our
business”, News.com.au reported.
The company was starting a Phase
IIb global clinical trial this year for
the drug, it said.The above article was sent to subscribers in Pharmacy Daily's issue from 14 Feb 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Feb 14
PEAK pharmacy bodies are calling on the Australian Government to extend the new Commonwealth Prac Payment to pharmacy students, citing the challenges of “placement poverty” in unpaid practical placements.
AFT Pharmaceuticals is set to develop a topical treatment for keloid and hypertrophic scarring in partnership with NZ’s Massey Ventures, the commercialisation arm of Massey University, and the Gillies McIndoe Research Institute.
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.